Drug-labels.com

Sandomigran: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Post Market
Strength:
0.50 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - Sandomigran

ABOUT THIS MEDICATION

What the medication is used for:

Sandomigran is prescribed for the prevention of migraine.

What it does:

When Sandomigran is taken regularly it can help to reduce the frequency or severity of migraine. Sandomigran is not intended for the treatment of acute migraines or to stop migraine attacks once they have started.

When it should not be used:

Do not use Sandomigran if you:

  • are allergic to this medicine, or to any of the components

    of its formulation (for a list of components, see the section “What the nonmedicinal ingredients are”);

  • take a monoamine oxidase inhibitor for treatment of

    depression (e.g.: Nardil®, Parnate®, Zynoxam®);

  • have a problem with food passing out of the stomach

    either from a complete or partial obstruction (pyloro-duonenal obstruction);

  • have an ulcer;
  • have intolerance to the sugar of milk products (or

    lactose).

  • are less than 12 years old

What the medicinal ingredient is:

Pizotifen hydrogen malate

What the nonmedicinal ingredients are:

Each 0.5 mg tablet contains: lactose monohydrate, corn starch, povidone, magnesium stearate, propyl paraben, acacia, colloidal silicone dioxide, cetyl palmitate, sugar and talc.

Each 1 mg tablet contains: lactose anhydrous, magnesium stearate, and microcrystalline cellulose.

What dosage forms it comes in:

Tablets; 0.5 mg (Sandomigran), 1 mg (Sandomigran DS)

WARNINGS AND PRECAUTIONS

Keep Sandomigran out of the reach of children. You should not give Sandomigran to anyone as inappropriate use may have severe medical consequences.

BEFORE you use Sandomigran talk to your doctor or pharmacist if you:

  • You have raised pressure in your eyes (glaucoma);
  • You have difficulty urinating;
  • You have a kidney or liver disease;
  • You have diabetes or heart disease
  • You have a history of seizure/epilepsy (convulsions)
  • You are pregnant, planning to become pregnant or you become pregnant while taking this medication.

  • You are breastfeeding or plan to breastfeed.
  • You have intolerance of sugar or lactose

Driving and operating machinery

Sandomigran may impair the mental and/or physical abilities required for performance of potentially hazardous task such as driving a car or operating machinery. If you experience drowsiness or dizziness, such tasks should be avoided.

Avoid alcoholic beverages or taking medications that can cause drowsiness (including sleeping pills, cold syrup, antidepressants etc.) while taking Sandomigran as they can increase the effect of drowsiness and dizziness.

Take this medication as directed by your doctor. Do not stop Sandomigran or Sandomigran DS without advice by your physician. Sudden stoppage of this drug may cause acute withdrawal reactions. Symptoms may include depression, tremor, nausea, anxiety, and/or sleep disorder etc.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor or pharmacist if you are taking or have recently taken any other prescription or over-the-counter medicines, vitamins or natural health products during your treatment with Sandomigran.

Drugs that may interact with Sandomigran & Sandomigran DS include:

  • Alcohol;
  • Sleeping pills, sedatives and antihistamines drugs (e.g.

    cold and hay fever medicines)

  • Low blood pressure drugs
  • Monoamine oxidase inhibitor (MAOI)

PROPER USE OF THIS MEDICATION

Adult and elderly:

The starting dose of Sandomigran is 0.5 mg once daily at bedtime. The daily dose can be increased gradually to a total dose of 1.5 mg administered at bedtime or in three divided doses if recommended by your physician.

Up to 3 mg may be given as a single dose.

Children (12 years and older):

The starting dose of Sandomigran is 0.5 mg once daily at bedtime. A maximum single dose of 1 mg can be given at bedtime. The overall daily dose can be increased gradually up to 1.5 mg divided into three 0.5 mg doses if recommended by your physician.

Overdose:

The symptoms of overdose may include sedation, drowsiness rapid heart rate, nausea, vomiting and lack of coordination of muscle movement.

Missed Dose:

If you normally take Sandomigran tablets 2 or more times a day you should take the last dose you missed as soon as you remember. Do not take it if there is less than 4 hours before your next dose, but go back to your regular dosing schedule. Do not double doses or take more than your maximum daily dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The most common side effects of Sandomigran are: increased appetite, weight gain, drowsiness, nausea, dry mouth, fatigue and dizziness.

Other side effects such as the following have also been observed: constipation, skin irritation, insomnia, anxiety, muscle and join pain, muscle cramps, delayed menstrual period, breast changes (pain, enlargement, secretion).

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effectTalk with your physician or pharmacistStop taking drug and seek emergency medical help
Only if severeIn all cases
Rare or very rareYellowing of the skin or eyes (jaundice)√
Persistent sad mood√
Aggressive behaviour or agitation in children√
Convulsions (seizures) or hallucination√
Sensation of tingling and/or pricking√
Partial or complete loss of vision√
Unknown

Allergic reaction

(symptoms include swelling in the mouth, tongue, face, and throat, itching, rash, blistering of the skin, and/or mucous membranes of the lips, eyes, mouth nasal passages or genitals)

✓

This is not a complete list of side effects. For any unexpected effects while taking Sandomigran or Sandomigran DS, contact your physician or pharmacist.

  • store your Sandomigran tablets at room temperature (between

    15-30°C)

  • protect from exposure to light and moisture
  • keep out of reach and sight of children
  • discard any expired medicine or medicine no longer needed

This document plus the full product monograph, prepared for health professionals can be found at:

http://www.website.document

or by contacting the sponsor, Paladin Labs Inc., at: 1-800-550-6060

Last revised: October 30, 2012

HOW TO STORE IT

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

--------------------------------------------------------------------------

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Canada Vigilance Reporting Form and:

    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program Health Canada

      Postal Locator 0701E

      Ottawa, Ontario

      K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 00329320

Revision date stated in the text: October 30, 2012

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Sandomigran

Rx or OTC
Prescription (Rx)?
DIN 00329320
Schedule(s) PRESCRIPTION
Active ingredient(s) Pizotifen (pizotifen malate) 0.5 MG
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. N Nervous system drugs
    1. N02 Analgesics
      1. N02C Antimigraine preparations
        1. N02CX Other antimigraine preparations
          1. N02CX01 Pizotifen
Company PALADIN PHARMA INC.
Current status Cancelled Post Market
Current status date July 28, 2021

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.